Epocrates Drug Updates - Editor's Pick

August 28, 2014
Tramadol Declared Schedule IV Drug

The DEA designated the synthetic opioid analgesic tramadol a Schedule IV substance, effective August 18, 2014. Its opioid activity and abuse potential are attributable to both the parent compound and a highly potent active metabolite, M1. Tramadol was previously an uncontrolled substance at the federal level, but its status varied by state, with multiple states already scheduling it as a C-IV drug.

Tramadol Declared Schedule IV Drug

Recent Updates

Aguust 28, 2014
Errata
The Delsym Cough + Cold Day Time monograph has been updated to correct the dosing for patients >12 years old to 20 mL PO q4h prn, with a maximum dose of 120 mL/24h.

The Tanzeum half-life was updated for consistency with the product’s labeling. Tanzeum has an elimination half-life of 5 days.

Please update your Epocrates app regularly to ensure that you always have the latest content.
Errata

August 14, 2014
Zydelig Approved for Three Types of Blood Cancers
The FDA recently approved Zydelig (idelalisib) for the treatment of three types of relapsed blood cancers: chronic lymphocytic leukemia (CLL), follicular B-cell non-Hodgkin lymphoma (FL), and small lymphocytic lymphoma (SLL). Zydelig is an oral phosphatidylinositol 3-kinase (PI3K) inhibitor and has a Boxed Warning for hepatotoxicity, severe diarrhea or colitis, pneumonitis, and intestinal perforation.
Zydelig Approved for Three Types of Blood Cancers

August 8, 2014
Beleodaq Approved for Relapsed or Refractory Peripheral T-cell Lymphoma
The FDA recently approved Beleodaq (belinostat), a new histone deacetylase (HDAC) inhibitor for the treatment of relapsed or refractory peripheral T-cell lymphoma. Beleodaq is given as an IV infusion once daily for 5 days each cycle.
Beleodaq Approved for Relapsed or Refractory Peripheral T-cell Lymphoma

July 24, 2014
Zontivity (Oral PAR-1 Inhibitor) Approved for Thrombotic Cardiovascular Events
The FDA recently approved Zontivity (vorapaxar), a once-daily, first-in-class protease-activated receptor-1 (PAR-1) antagonist for the prevention of heart attack and stroke in patients with peripheral arterial disease or a history of myocardial infarction.
Zontivity (Oral PAR-1 Inhibitor) Approved for Thrombotic Cardiovascular Events

July 17, 2014
Dalvance Approved for Acute Bacterial Skin and Skin Structure Infections in Adults
The FDA recently approved Dalvance (dalbavancin), a new lipoglycopeptide antibacterial for skin and skin structure infections caused by certain gram-positive microorganisms, including methicillin-resistant Staphylococcus aureus (MRSA). Dalvance is available as an IV infusion, and is given once weekly for 2 consecutive weeks.
Dalvance Approved for Acute Bacterial Skin and Skin Structure Infections in Adults

New Drug Monographs

What is an RSS Feed?

From Wikipedia: "RSS is a simple XML-based system that allows users to subscribe to their favorite websites. Using RSS, webmasters can put their content into a standardized format, which can be viewed and organized through RSS-aware software or automatically conveyed as new content on another website."

email Subscribe by email

Enter your email address:


   Cancel

Delivered by FeedBurner